TP53 and breast carcinoma: To study the effect of ABCG2 inhibition on topotecan efficacy in a tumor-specific fashion, we transplanted spontaneous ABCG2-proficient Brca1−/−;p53−/− mammary carcinomas [25], derived on a FVB/N background, orthotopically into ABCG2-deficient recipients [26] of the same mouse strain (Fig. 1A).